4B CEDAR BROOK DRIVE, CRANBURY, NJ
To Begin Trading on Nasdaq Stock Exchange
Amended material disclosure
Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option
Announces Pricing of Upsized $15.8 Million Public Offering
Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration
Other Events
To develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Q3
Q2
Q1
FY 2025
FY 2024
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
S-1
Direct Registration System
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence